<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	>

<channel>
	<title>PR Hub &#187; Medical Equipment</title>
	<atom:link href="http://pr.gaeatimes.com/c/health/medical-equipment/feed/" rel="self" type="application/rss+xml" />
	<link>http://pr.gaeatimes.com</link>
	<description></description>
	<pubDate>Fri, 16 Dec 2011 13:12:07 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.7.1</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>ThromboGenics and BioInvent Complete Enrollment of Phase IIb Trial With TB-402 Ahead of Schedule</title>
		<link>http://pr.gaeatimes.com/thrombogenics-and-bioinvent-complete-enrollment-of-phase-iib-trial-with-tb-402-ahead-of-schedule-54941/</link>
		<comments>http://pr.gaeatimes.com/thrombogenics-and-bioinvent-complete-enrollment-of-phase-iib-trial-with-tb-402-ahead-of-schedule-54941/#comments</comments>
		<pubDate>Fri, 16 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Thrombogenics</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Clinical Trials / Medical Discoveries]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[belgium]]></category>

		<category><![CDATA[Belgium And Lund]]></category>

		<category><![CDATA[December 16]]></category>

		<category><![CDATA[Leuven]]></category>

		<category><![CDATA[sweden]]></category>

		<category><![CDATA[Thrombogenics]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/thrombogenics-and-bioinvent-complete-enrollment-of-phase-iib-trial-with-tb-402-ahead-of-schedule-54941/</guid>
		<description><![CDATA[LEUVEN, Belgium and LUND, Sweden, December 16, 2011  -

ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce today that they have completed the enrolment of a 632-patient Phase IIb trial with their novel long-acting anticoagulant TB-402 (factor VIII inhibitor) for the prophylaxis of venous thromboembolism (VTE) after total hip surgery. .... Original article on Gaea Times at  &nbsp;: <a href="http://pr.gaeatimes.com/thrombogenics-and-bioinvent-complete-enrollment-of-phase-iib-trial-with-tb-402-ahead-of-schedule-54941/">ThromboGenics and BioInvent Complete Enrollment of Phase IIb Trial With TB-402 Ahead of Schedule</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/thrombogenics-and-bioinvent-complete-enrollment-of-phase-iib-trial-with-tb-402-ahead-of-schedule-54941/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Hospital Operating Rooms are now Optimized in Real-time With a Joint Solution From Karl Storz and Ekahau</title>
		<link>http://pr.gaeatimes.com/hospital-operating-rooms-are-now-optimized-in-real-time-with-a-joint-solution-from-karl-storz-and-ekahau-54950/</link>
		<comments>http://pr.gaeatimes.com/hospital-operating-rooms-are-now-optimized-in-real-time-with-a-joint-solution-from-karl-storz-and-ekahau-54950/#comments</comments>
		<pubDate>Fri, 16 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Ekahau</dc:creator>
		
		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Investors]]></category>

		<category><![CDATA[Joint Ventures]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[New Products / Services]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[December 16]]></category>

		<category><![CDATA[Ekahau]]></category>

		<category><![CDATA[Reston]]></category>

		<category><![CDATA[virginia]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/hospital-operating-rooms-are-now-optimized-in-real-time-with-a-joint-solution-from-karl-storz-and-ekahau-54950/</guid>
		<description><![CDATA[RESTON, Virginia, December 16, 2011  -

Ekahau Inc. the leading global provider of high performance Wi-Fi-based Real-Time Location Systems (RTLS), and KARL STORZ GmbH &#38; Co. KG, the endoscopy specialist, announced today a joint solution for OR management. The MIC Clinic in Berlin has successfully deployed and is using the combined solution of Karl Storz ... Read : <a href="http://pr.gaeatimes.com/hospital-operating-rooms-are-now-optimized-in-real-time-with-a-joint-solution-from-karl-storz-and-ekahau-54950/">Hospital Operating Rooms are now Optimized in Real-time With a Joint Solution From Karl Storz and Ekahau</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/hospital-operating-rooms-are-now-optimized-in-real-time-with-a-joint-solution-from-karl-storz-and-ekahau-54950/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Health Robotics Continues Worldwide Expansion in Denmark With 2nd Generation Robots and Novamed</title>
		<link>http://pr.gaeatimes.com/health-robotics-continues-worldwide-expansion-in-denmark-with-2nd-generation-robots-and-novamed-54970/</link>
		<comments>http://pr.gaeatimes.com/health-robotics-continues-worldwide-expansion-in-denmark-with-2nd-generation-robots-and-novamed-54970/#comments</comments>
		<pubDate>Fri, 16 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Health Robotics</dc:creator>
		
		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[New Products / Services]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Bozen]]></category>

		<category><![CDATA[December 16]]></category>

		<category><![CDATA[Health Robotics]]></category>

		<category><![CDATA[Italy]]></category>

		<category><![CDATA[Sud-tirol]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/health-robotics-continues-worldwide-expansion-in-denmark-with-2nd-generation-robots-and-novamed-54970/</guid>
		<description><![CDATA[BOZEN, Sud-Tirol, Italy, December 16, 2011  -

After successfully switching marketing channel strategies from certain non-performing indirect distribution channels in several countries to Health Robotics&#8217; direct management in 1Q2011, the company today announced the extension of the same control over local operations in Denmark, in partnership with local Oncology leader Novamed.
Ulrich R. Andersen, Novamed&#8217;s Managing ... <a href="http://pr.gaeatimes.com/health-robotics-continues-worldwide-expansion-in-denmark-with-2nd-generation-robots-and-novamed-54970/">Read : Health Robotics Continues Worldwide Expansion in Denmark With 2nd Generation Robots and Novamed</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/health-robotics-continues-worldwide-expansion-in-denmark-with-2nd-generation-robots-and-novamed-54970/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Babies are Dying Needlessly in the UK Through Ignorance and Unavailability of Tests Routinely Offered in Other Western Countries</title>
		<link>http://pr.gaeatimes.com/babies-are-dying-needlessly-in-the-uk-through-ignorance-and-unavailability-of-tests-routinely-offered-in-other-western-countries-54885/</link>
		<comments>http://pr.gaeatimes.com/babies-are-dying-needlessly-in-the-uk-through-ignorance-and-unavailability-of-tests-routinely-offered-in-other-western-countries-54885/#comments</comments>
		<pubDate>Thu, 15 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Group B Strep Support</dc:creator>
		
		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Surveys / Polls / Research]]></category>

		<category><![CDATA[December 15]]></category>

		<category><![CDATA[Group B Strep Support]]></category>

		<category><![CDATA[London]]></category>

		<category><![CDATA[United Kingdom]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/babies-are-dying-needlessly-in-the-uk-through-ignorance-and-unavailability-of-tests-routinely-offered-in-other-western-countries-54885/</guid>
		<description><![CDATA[LONDON, December 15, 2011  -
A new opinion poll has found that most young women support the introduction of a national screening programme to detect Group B Strep in pregnant women.

A recent survey conducted by ComRes on behalf of Group B Strep Support demonstrated that while more than half (54%) the women aged between 20-35 .... Source article &nbsp;: <a href="http://pr.gaeatimes.com/babies-are-dying-needlessly-in-the-uk-through-ignorance-and-unavailability-of-tests-routinely-offered-in-other-western-countries-54885/">Babies are Dying Needlessly in the UK Through Ignorance and Unavailability of Tests Routinely Offered in Other Western Countries</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/babies-are-dying-needlessly-in-the-uk-through-ignorance-and-unavailability-of-tests-routinely-offered-in-other-western-countries-54885/feed/</wfw:commentRss>
		</item>
		<item>
		<title>World’s First Curve(TM) Image Guided Surgery System Now Operating in Germany</title>
		<link>http://pr.gaeatimes.com/world%e2%80%99s-first-curvetm-image-guided-surgery-system-now-operating-in-germany-54886/</link>
		<comments>http://pr.gaeatimes.com/world%e2%80%99s-first-curvetm-image-guided-surgery-system-now-operating-in-germany-54886/#comments</comments>
		<pubDate>Thu, 15 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Brainlab Ag</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[New Products / Services]]></category>

		<category><![CDATA[Brainlab Ag]]></category>

		<category><![CDATA[December 15]]></category>

		<category><![CDATA[Germany]]></category>

		<category><![CDATA[Munich]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/world%e2%80%99s-first-curvetm-image-guided-surgery-system-now-operating-in-germany-54886/</guid>
		<description><![CDATA[MUNICH, December 15, 2011  -
Highly advanced surgical navigation system to enable faster, more precise and safer surgery

This week, university hospital Klinikum rechts der Isar in Munich, Germany, is the first hospital in the world to operate with Brainlab&#8217;s Curve&#8482; Image Guided Surgery system. The new technology is hoped to provide surgeons with the best .... Source article on Gaea Times at  &nbsp;: <a href="http://pr.gaeatimes.com/world%e2%80%99s-first-curvetm-image-guided-surgery-system-now-operating-in-germany-54886/">World’s First Curve(TM) Image Guided Surgery System Now Operating in Germany</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/world%e2%80%99s-first-curvetm-image-guided-surgery-system-now-operating-in-germany-54886/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Amphetamobile Develops AMMO RACK App for SciVerse Applications</title>
		<link>http://pr.gaeatimes.com/amphetamobile-develops-ammo-rack-app-for-sciverse-applications-54898/</link>
		<comments>http://pr.gaeatimes.com/amphetamobile-develops-ammo-rack-app-for-sciverse-applications-54898/#comments</comments>
		<pubDate>Thu, 15 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Elsevier</dc:creator>
		
		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Media]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[New Products / Services]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Amsterdam]]></category>

		<category><![CDATA[December 15]]></category>

		<category><![CDATA[Elsevier]]></category>

		<category><![CDATA[Netherlands]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/amphetamobile-develops-ammo-rack-app-for-sciverse-applications-54898/</guid>
		<description><![CDATA[AMSTERDAM, December 15, 2011  -

Researchers to save and organize content for mobile use with document management app

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the availability of the AMMO RACK app on SciVerse Applications. Developed by mobile platform developer Amphetamobile (AMMO), the application enables users to save .... Original article on Gaea Times at  &nbsp;: <a href="http://pr.gaeatimes.com/amphetamobile-develops-ammo-rack-app-for-sciverse-applications-54898/">Amphetamobile Develops AMMO RACK App for SciVerse Applications</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/amphetamobile-develops-ammo-rack-app-for-sciverse-applications-54898/feed/</wfw:commentRss>
		</item>
		<item>
		<title>CORRECTION - Brainlab AG: World’s First Curve(TM) Image Guided Surgery System Now Operating in Germany</title>
		<link>http://pr.gaeatimes.com/correction-brainlab-ag-world%e2%80%99s-first-curvetm-image-guided-surgery-system-now-operating-in-germany-54935/</link>
		<comments>http://pr.gaeatimes.com/correction-brainlab-ag-world%e2%80%99s-first-curvetm-image-guided-surgery-system-now-operating-in-germany-54935/#comments</comments>
		<pubDate>Thu, 15 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Brainlab Ag</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[New Products / Services]]></category>

		<category><![CDATA[Brainlab Ag]]></category>

		<category><![CDATA[December 15]]></category>

		<category><![CDATA[Germany]]></category>

		<category><![CDATA[Munich]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/correction-brainlab-ag-world%e2%80%99s-first-curvetm-image-guided-surgery-system-now-operating-in-germany-54935/</guid>
		<description><![CDATA[MUNICH, December 15, 2011  -
In the news release, &#8220;World&#8217;s First Curve(TM) Image Guided Surgery System Now Operating in Germany&#8221; issued on 15 Dec 2011 09:12 GMT, by Brainlab AG over PR Newswire, we are advised by a representative of the company that some minor changes were required to be made within the first paragraph .... Original article on Gaea Times at  &nbsp;: <a href="http://pr.gaeatimes.com/correction-brainlab-ag-world%e2%80%99s-first-curvetm-image-guided-surgery-system-now-operating-in-germany-54935/">CORRECTION - Brainlab AG: World’s First Curve(TM) Image Guided Surgery System Now Operating in Germany</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/correction-brainlab-ag-world%e2%80%99s-first-curvetm-image-guided-surgery-system-now-operating-in-germany-54935/feed/</wfw:commentRss>
		</item>
		<item>
		<title>A New International Congress on Regenerative Medicine Held With Great Success by Cryo-Save in Bosnia</title>
		<link>http://pr.gaeatimes.com/a-new-international-congress-on-regenerative-medicine-held-with-great-success-by-cryo-save-in-bosnia-54794/</link>
		<comments>http://pr.gaeatimes.com/a-new-international-congress-on-regenerative-medicine-held-with-great-success-by-cryo-save-in-bosnia-54794/#comments</comments>
		<pubDate>Wed, 14 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Cryo-save Ag</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Clinical Trials / Medical Discoveries]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Cryo-save Ag]]></category>

		<category><![CDATA[December 14]]></category>

		<category><![CDATA[Netherlands]]></category>

		<category><![CDATA[The Netherlands]]></category>

		<category><![CDATA[Zutphen]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/a-new-international-congress-on-regenerative-medicine-held-with-great-success-by-cryo-save-in-bosnia-54794/</guid>
		<description><![CDATA[ZUTPHEN, The Netherlands, December 14, 2011  -

It is part of Cryo-Save&#8217;s educational program deployment to increase the awareness of stem cells therapy and regenerative medicine amongst healthcare professionals.
The Second international congress &#8220;Regenerative medicine - stem cells, genetic engineering and biotechnology&#8221; was held on December 9 in Sarajevo, supported by the Institute for Genetic Engineering .... Source article on Gaea Times at  &nbsp;: <a href="http://pr.gaeatimes.com/a-new-international-congress-on-regenerative-medicine-held-with-great-success-by-cryo-save-in-bosnia-54794/">A New International Congress on Regenerative Medicine Held With Great Success by Cryo-Save in Bosnia</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/a-new-international-congress-on-regenerative-medicine-held-with-great-success-by-cryo-save-in-bosnia-54794/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Coloplast Makes More Products, Emits Less CO2</title>
		<link>http://pr.gaeatimes.com/coloplast-makes-more-products-emits-less-co2-54799/</link>
		<comments>http://pr.gaeatimes.com/coloplast-makes-more-products-emits-less-co2-54799/#comments</comments>
		<pubDate>Wed, 14 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Coloplast As</dc:creator>
		
		<category><![CDATA[Conservation / Recycling]]></category>

		<category><![CDATA[Environment]]></category>

		<category><![CDATA[Environmental Issues]]></category>

		<category><![CDATA[Government and Policy]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Coloplast A/s]]></category>

		<category><![CDATA[December 14]]></category>

		<category><![CDATA[denmark]]></category>

		<category><![CDATA[Hmlebaek]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/coloplast-makes-more-products-emits-less-co2-54799/</guid>
		<description><![CDATA[HMLEBAEK, Denmark, December 14, 2011  -

For the first time, the medical device company Coloplast sets a target for reducing its CO2 emissions from production. The goal is an absolute reduction of 10 percent* in the next three years.
To view the Multimedia News Release, please click:
multivu.prnewswire.com/mnr/prne/coloplastas/52802/
&#8220;Even though we expect an 8 percent increase in production, ... <a href="http://pr.gaeatimes.com/coloplast-makes-more-products-emits-less-co2-54799/">Read this article on Gaea Times at  : Coloplast Makes More Products, Emits Less CO2</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/coloplast-makes-more-products-emits-less-co2-54799/feed/</wfw:commentRss>
		</item>
		<item>
		<title>No European Scientists Left by 2020?</title>
		<link>http://pr.gaeatimes.com/no-european-scientists-left-by-2020-54822/</link>
		<comments>http://pr.gaeatimes.com/no-european-scientists-left-by-2020-54822/#comments</comments>
		<pubDate>Wed, 14 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Eun Partnership Aisbl</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Business]]></category>

		<category><![CDATA[Children Related]]></category>

		<category><![CDATA[Education]]></category>

		<category><![CDATA[Environment]]></category>

		<category><![CDATA[Government and Policy]]></category>

		<category><![CDATA[Green Technology]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Higher Education]]></category>

		<category><![CDATA[Machinery]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Multicultural]]></category>

		<category><![CDATA[New Products / Services]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Surveys / Polls / Research]]></category>

		<category><![CDATA[Technology]]></category>

		<category><![CDATA[Women Related]]></category>

		<category><![CDATA[belgium]]></category>

		<category><![CDATA[Brussels]]></category>

		<category><![CDATA[December 14]]></category>

		<category><![CDATA[Eun Partnership Aisbl]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/no-european-scientists-left-by-2020-54822/</guid>
		<description><![CDATA[BRUSSELS, December 14, 2011  -
Business Leaders, European Schoolnet and the European Commission launch &#8364;8.3mn initiative to encourage teenagers to study science and maths

European business leaders and education policy makers have launched today an &#8364;8.3mn initiative to inspire students to study science at university - a much needed skill set if the region&#8217;s economy is .... Original article &nbsp;: <a href="http://pr.gaeatimes.com/no-european-scientists-left-by-2020-54822/">No European Scientists Left by 2020?</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/no-european-scientists-left-by-2020-54822/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Visongain&#8217;s Report Predicts That Medical Biobanking Market Will Reach 19.1 Bllion Dollars in 2015</title>
		<link>http://pr.gaeatimes.com/visongains-report-predicts-that-medical-biobanking-market-will-reach-191-bllion-dollars-in-2015-54826/</link>
		<comments>http://pr.gaeatimes.com/visongains-report-predicts-that-medical-biobanking-market-will-reach-191-bllion-dollars-in-2015-54826/#comments</comments>
		<pubDate>Wed, 14 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Visiongain</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Surveys / Polls / Research]]></category>

		<category><![CDATA[December 14]]></category>

		<category><![CDATA[London]]></category>

		<category><![CDATA[United Kingdom]]></category>

		<category><![CDATA[Visiongain]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/visongains-report-predicts-that-medical-biobanking-market-will-reach-191-bllion-dollars-in-2015-54826/</guid>
		<description><![CDATA[LONDON, December 14, 2011  -
www.visiongain.com/Report/734/Biobanking-for-Medicine-Technology-and-Market-2012-2022

A new report by visiongain, a London-based business information company, predicts that world medical biobanking revenues will reach $19.1bn in 2015. That market generated $9.0bn in 2010, according to Biobanking for Medicine: Technology and Market 2012-2022, published in December 2011.
The market for medical biobanking technologies and services has expanded rapidly. ... Read more <a href="http://pr.gaeatimes.com/visongains-report-predicts-that-medical-biobanking-market-will-reach-191-bllion-dollars-in-2015-54826/" title="Visongain&#8217;s Report Predicts That Medical Biobanking Market Will Reach 19.1 Bllion Dollars in 2015">&raquo;&raquo;&raquo;</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/visongains-report-predicts-that-medical-biobanking-market-will-reach-191-bllion-dollars-in-2015-54826/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Carl Zeiss: Revenue Tops Four Billion Euro Mark for Very First Time</title>
		<link>http://pr.gaeatimes.com/carl-zeiss-revenue-tops-four-billion-euro-mark-for-very-first-time-54829/</link>
		<comments>http://pr.gaeatimes.com/carl-zeiss-revenue-tops-four-billion-euro-mark-for-very-first-time-54829/#comments</comments>
		<pubDate>Wed, 14 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Carl Zeiss Ag</dc:creator>
		
		<category><![CDATA[Banking and Financial Services]]></category>

		<category><![CDATA[Earnings]]></category>

		<category><![CDATA[Earnings Projections / Forecasts]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Investors]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Sales Reports]]></category>

		<category><![CDATA[Semiconductors]]></category>

		<category><![CDATA[Technology]]></category>

		<category><![CDATA[Carl Zeiss Ag]]></category>

		<category><![CDATA[December 14]]></category>

		<category><![CDATA[Germany]]></category>

		<category><![CDATA[Stuttgart]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/carl-zeiss-revenue-tops-four-billion-euro-mark-for-very-first-time-54829/</guid>
		<description><![CDATA[STUTTGART, Germany, December 14, 2011  -

Carl Zeiss Group continues to invest in technology, infrastructure and internationalization
    - Vision Care business group fully consolidated
    - Well positioned against background of global economic uncertainty
Carl Zeiss has now presented its annual financial statements. In fiscal year 2010/11, the company generated revenues of EUR 4.237b (prior ... Read : <a href="http://pr.gaeatimes.com/carl-zeiss-revenue-tops-four-billion-euro-mark-for-very-first-time-54829/">Carl Zeiss: Revenue Tops Four Billion Euro Mark for Very First Time</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/carl-zeiss-revenue-tops-four-billion-euro-mark-for-very-first-time-54829/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Bright Light Therapy via Ear Canals Improved Reaction Times of Top Athletes in a Placebo-Controlled Psycho-Motoric Study</title>
		<link>http://pr.gaeatimes.com/bright-light-therapy-via-ear-canals-improved-reaction-times-of-top-athletes-in-a-placebo-controlled-psycho-motoric-study-54832/</link>
		<comments>http://pr.gaeatimes.com/bright-light-therapy-via-ear-canals-improved-reaction-times-of-top-athletes-in-a-placebo-controlled-psycho-motoric-study-54832/#comments</comments>
		<pubDate>Wed, 14 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Valkee</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Clinical Trials / Medical Discoveries]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Sports]]></category>

		<category><![CDATA[December 14]]></category>

		<category><![CDATA[finland]]></category>

		<category><![CDATA[Helsinki]]></category>

		<category><![CDATA[Valkee]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/bright-light-therapy-via-ear-canals-improved-reaction-times-of-top-athletes-in-a-placebo-controlled-psycho-motoric-study-54832/</guid>
		<description><![CDATA[HELSINKI, December 14, 2011  -
A placebo controlled study involving top ice hockey players from the Finnish national league has shown motoric reaction times reduced by one fifth in players using the Valkee bright light headset. In the treatment group, the athletes were given 12 minutes of bright light via the ear canal each morning ... Read more <a href="http://pr.gaeatimes.com/bright-light-therapy-via-ear-canals-improved-reaction-times-of-top-athletes-in-a-placebo-controlled-psycho-motoric-study-54832/" title="Bright Light Therapy via Ear Canals Improved Reaction Times of Top Athletes in a Placebo-Controlled Psycho-Motoric Study">>>></a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/bright-light-therapy-via-ear-canals-improved-reaction-times-of-top-athletes-in-a-placebo-controlled-psycho-motoric-study-54832/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery</title>
		<link>http://pr.gaeatimes.com/edoxaban-significantly-reduces-risk-of-venous-thromboembolism-by-half-compared-to-enoxaparin-in-japanese-and-taiwanese-patients-following-knee-or-hip-arthroplasty-surgery-54715/</link>
		<comments>http://pr.gaeatimes.com/edoxaban-significantly-reduces-risk-of-venous-thromboembolism-by-half-compared-to-enoxaparin-in-japanese-and-taiwanese-patients-following-knee-or-hip-arthroplasty-surgery-54715/#comments</comments>
		<pubDate>Tue, 13 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Daiichi Sankyo Company Limited</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Clinical Trials / Medical Discoveries]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Daiichi Sankyo Company Limited]]></category>

		<category><![CDATA[December 13]]></category>

		<category><![CDATA[December 14]]></category>

		<category><![CDATA[Germany]]></category>

		<category><![CDATA[Japan]]></category>

		<category><![CDATA[Munich]]></category>

		<category><![CDATA[taiwan]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/edoxaban-significantly-reduces-risk-of-venous-thromboembolism-by-half-compared-to-enoxaparin-in-japanese-and-taiwanese-patients-following-knee-or-hip-arthroplasty-surgery-54715/</guid>
		<description><![CDATA[MUNICH, December 14, 2011  -

Pooled results of the STARS E-III and STARS J-V studies presented at the 2011 American Society of Hematology (ASH) Annual Meeting
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the results of a pooled analysis showing that edoxaban*, a direct oral once-daily factor Xa inhibitor, significantly reduced the risk of developing venous thromboembolism (VTE)  [..] <a href="http://pr.gaeatimes.com/edoxaban-significantly-reduces-risk-of-venous-thromboembolism-by-half-compared-to-enoxaparin-in-japanese-and-taiwanese-patients-following-knee-or-hip-arthroplasty-surgery-54715/">Read the original article: here</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/edoxaban-significantly-reduces-risk-of-venous-thromboembolism-by-half-compared-to-enoxaparin-in-japanese-and-taiwanese-patients-following-knee-or-hip-arthroplasty-surgery-54715/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Pieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin(R) Program at ASH Annual Meeting</title>
		<link>http://pr.gaeatimes.com/pieris-presents-preclinical-data-for-prs-080-hepcidin-antagonist-anticalinr-program-at-ash-annual-meeting-54742/</link>
		<comments>http://pr.gaeatimes.com/pieris-presents-preclinical-data-for-prs-080-hepcidin-antagonist-anticalinr-program-at-ash-annual-meeting-54742/#comments</comments>
		<pubDate>Tue, 13 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Pieris Ag</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Clinical Trials / Medical Discoveries]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[california]]></category>

		<category><![CDATA[December 13]]></category>

		<category><![CDATA[Pieris AG]]></category>

		<category><![CDATA[San diego]]></category>

		<category><![CDATA[United States of America]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/pieris-presents-preclinical-data-for-prs-080-hepcidin-antagonist-anticalinr-program-at-ash-annual-meeting-54742/</guid>
		<description><![CDATA[SAN DIEGO, California, December 13, 2011  -

&#8211; Breadth of Pharmacokinetic Data Points to Tunable Half-life for Platform &#8211;
Pieris AG presented novel preclinical in vitro and in vivo data for its PRS-080 Anticalin hepcidin antagonist in an oral presentation at the American Society of Hematology Annual Meeting, the company announced today.  In a presentation entitled ... Read more : <a href="http://pr.gaeatimes.com/pieris-presents-preclinical-data-for-prs-080-hepcidin-antagonist-anticalinr-program-at-ash-annual-meeting-54742/">Pieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin(R) Program at ASH Annual Meeting</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/pieris-presents-preclinical-data-for-prs-080-hepcidin-antagonist-anticalinr-program-at-ash-annual-meeting-54742/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Molecular Imaging, Inc. Enters Relationship with Dana-Farber Cancer Institute to Expand Luciferase-reporter Cancer Cell Lines for Preclinical in vivo Imaging</title>
		<link>http://pr.gaeatimes.com/molecular-imaging-inc-enters-relationship-with-dana-farber-cancer-institute-to-expand-luciferase-reporter-cancer-cell-lines-for-preclinical-in-vivo-imaging-54783/</link>
		<comments>http://pr.gaeatimes.com/molecular-imaging-inc-enters-relationship-with-dana-farber-cancer-institute-to-expand-luciferase-reporter-cancer-cell-lines-for-preclinical-in-vivo-imaging-54783/#comments</comments>
		<pubDate>Tue, 13 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Molecular Imaging Inc.</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Licensing / Marketing Agreements]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Mental Health]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Ann arbor]]></category>

		<category><![CDATA[December 13]]></category>

		<category><![CDATA[Michigan]]></category>

		<category><![CDATA[Molecular Imaging Inc.]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/molecular-imaging-inc-enters-relationship-with-dana-farber-cancer-institute-to-expand-luciferase-reporter-cancer-cell-lines-for-preclinical-in-vivo-imaging-54783/</guid>
		<description><![CDATA[ANN ARBOR, Michigan, December 13, 2011  -

Molecular Imaging, Inc. (Molecular Imaging), a specialty contract research organization providing multi-modality preclinical in vivo imaging services to pharmaceutical and biotechnology companies, today announced that it has entered into a licensing agreement with Dana-Farber Cancer Institute to access a substantial number of luciferase-enabled cancer cell lines developed at ... Original source on Gaea Times at  : <a href="http://pr.gaeatimes.com/molecular-imaging-inc-enters-relationship-with-dana-farber-cancer-institute-to-expand-luciferase-reporter-cancer-cell-lines-for-preclinical-in-vivo-imaging-54783/">Molecular Imaging, Inc. Enters Relationship with Dana-Farber Cancer Institute to Expand Luciferase-reporter Cancer Cell Lines for Preclinical in vivo Imaging</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/molecular-imaging-inc-enters-relationship-with-dana-farber-cancer-institute-to-expand-luciferase-reporter-cancer-cell-lines-for-preclinical-in-vivo-imaging-54783/feed/</wfw:commentRss>
		</item>
		<item>
		<title>ViroPharma&#8217;s Buccolam®▼ (Midazolam, Oromucosal Solution) now Available in the United Kingdom as Licenced Product for Emergency Treatment of Seizures in Children and Adolescents</title>
		<link>http://pr.gaeatimes.com/viropharmas-buccolam%c2%ae%e2%96%bc-midazolam-oromucosal-solution-now-available-in-the-united-kingdom-as-licenced-product-for-emergency-treatment-of-seizures-in-children-and-adolescents-54648/</link>
		<comments>http://pr.gaeatimes.com/viropharmas-buccolam%c2%ae%e2%96%bc-midazolam-oromucosal-solution-now-available-in-the-united-kingdom-as-licenced-product-for-emergency-treatment-of-seizures-in-children-and-adolescents-54648/#comments</comments>
		<pubDate>Mon, 12 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Viropharma Incorporated</dc:creator>
		
		<category><![CDATA[Children Related]]></category>

		<category><![CDATA[Clinical Trials / Medical Discoveries]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Multicultural]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[December 12]]></category>

		<category><![CDATA[Exton]]></category>

		<category><![CDATA[Pennsylvania]]></category>

		<category><![CDATA[Viropharma Incorporated]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/viropharmas-buccolam%c2%ae%e2%96%bc-midazolam-oromucosal-solution-now-available-in-the-united-kingdom-as-licenced-product-for-emergency-treatment-of-seizures-in-children-and-adolescents-54648/</guid>
		<description><![CDATA[EXTON, Pennsylvania, December 12, 2011  -

Clinicians and carers of children and adolescents suffering from prolonged, acute, convulsive seizures now have access to Buccolam® (midazolam oromucosal solution), a newly approved rescue medication to treat prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years of age.[1] For .... <a href="http://pr.gaeatimes.com/viropharmas-buccolam%c2%ae%e2%96%bc-midazolam-oromucosal-solution-now-available-in-the-united-kingdom-as-licenced-product-for-emergency-treatment-of-seizures-in-children-and-adolescents-54648/">Source &nbsp;: ViroPharma&#8217;s Buccolam®▼ (Midazolam, Oromucosal Solution) now Available in the United Kingdom as Licenced Product for Emergency Treatment of Seizures in Children and Adolescents</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/viropharmas-buccolam%c2%ae%e2%96%bc-midazolam-oromucosal-solution-now-available-in-the-united-kingdom-as-licenced-product-for-emergency-treatment-of-seizures-in-children-and-adolescents-54648/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Leading Medical Device Manufacturers of CE-Marked THV Devices Sign Contracts with ClinFlows</title>
		<link>http://pr.gaeatimes.com/leading-medical-device-manufacturers-of-ce-marked-thv-devices-sign-contracts-with-clinflows-54650/</link>
		<comments>http://pr.gaeatimes.com/leading-medical-device-manufacturers-of-ce-marked-thv-devices-sign-contracts-with-clinflows-54650/#comments</comments>
		<pubDate>Mon, 12 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Clinflows</dc:creator>
		
		<category><![CDATA[Contracts]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Investors]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Clinflows]]></category>

		<category><![CDATA[December 12]]></category>

		<category><![CDATA[Germany]]></category>

		<category><![CDATA[Hüllhorst]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/leading-medical-device-manufacturers-of-ce-marked-thv-devices-sign-contracts-with-clinflows-54650/</guid>
		<description><![CDATA[HÜLLHORST, Germany, December 12, 2011  -

All CE-marked THV devices use ClinFlows decidemedical online platform
ClinFlows, the leading provider of configurable e-solutions for clinical workflows, has signed contracts with all companies selling CE marked THV (Transcatheter Heart Valve) devices in Europe.
THV device manufacturers are involved in projects using ClinFlows´ decidemedical online platform to support clinical proctoring .... Original source &nbsp;: <a href="http://pr.gaeatimes.com/leading-medical-device-manufacturers-of-ce-marked-thv-devices-sign-contracts-with-clinflows-54650/">Leading Medical Device Manufacturers of CE-Marked THV Devices Sign Contracts with ClinFlows</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/leading-medical-device-manufacturers-of-ce-marked-thv-devices-sign-contracts-with-clinflows-54650/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Nonin Medical Announces the European Launch of EQUANOX Advance™ Neonatal/Pediatric Sensor for Regional Oximetry at PGA Conference</title>
		<link>http://pr.gaeatimes.com/nonin-medical-announces-the-european-launch-of-equanox-advance%e2%84%a2-neonatalpediatric-sensor-for-regional-oximetry-at-pga-conference-54705/</link>
		<comments>http://pr.gaeatimes.com/nonin-medical-announces-the-european-launch-of-equanox-advance%e2%84%a2-neonatalpediatric-sensor-for-regional-oximetry-at-pga-conference-54705/#comments</comments>
		<pubDate>Mon, 12 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Nonin Medical Inc.</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Business]]></category>

		<category><![CDATA[Children Related]]></category>

		<category><![CDATA[Computer / Electronics]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Multicultural]]></category>

		<category><![CDATA[New Products / Services]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Technology]]></category>

		<category><![CDATA[December 12]]></category>

		<category><![CDATA[Minneapolis]]></category>

		<category><![CDATA[Minnesota]]></category>

		<category><![CDATA[Nonin Medical Inc.]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/nonin-medical-announces-the-european-launch-of-equanox-advance%e2%84%a2-neonatalpediatric-sensor-for-regional-oximetry-at-pga-conference-54705/</guid>
		<description><![CDATA[MINNEAPOLIS, December 12, 2011  -


Nonin Medical, Inc., the inventor of finger pulse oximeters and a 25-year leader in noninvasive medical monitoring, announced the European launch of an innovative pediatric sensor for use with the company&#8217;s EQUANOX&#8482; Regional Oximetry System. Nonin made the announcement at the 65th Annual Post Graduate Assembly in New York.
The EQUANOX ... Read the original article on Gaea Times at  : <a href="http://pr.gaeatimes.com/nonin-medical-announces-the-european-launch-of-equanox-advance%e2%84%a2-neonatalpediatric-sensor-for-regional-oximetry-at-pga-conference-54705/">Nonin Medical Announces the European Launch of EQUANOX Advance™ Neonatal/Pediatric Sensor for Regional Oximetry at PGA Conference</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/nonin-medical-announces-the-european-launch-of-equanox-advance%e2%84%a2-neonatalpediatric-sensor-for-regional-oximetry-at-pga-conference-54705/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Landmark VISTA Trial Shows Significant Long-Term Overall Survival Benefit of VELCADE® (Bortezomib) in Patients With Previously Untreated Multiple Myeloma</title>
		<link>http://pr.gaeatimes.com/landmark-vista-trial-shows-significant-long-term-overall-survival-benefit-of-velcade%c2%ae-bortezomib-in-patients-with-previously-untreated-multiple-myeloma-54712/</link>
		<comments>http://pr.gaeatimes.com/landmark-vista-trial-shows-significant-long-term-overall-survival-benefit-of-velcade%c2%ae-bortezomib-in-patients-with-previously-untreated-multiple-myeloma-54712/#comments</comments>
		<pubDate>Mon, 12 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Janssen Pharmaceuticals Nv</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Clinical Trials / Medical Discoveries]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Beerse]]></category>

		<category><![CDATA[belgium]]></category>

		<category><![CDATA[December 12]]></category>

		<category><![CDATA[Janssen Pharmaceuticals Nv]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/landmark-vista-trial-shows-significant-long-term-overall-survival-benefit-of-velcade%c2%ae-bortezomib-in-patients-with-previously-untreated-multiple-myeloma-54712/</guid>
		<description><![CDATA[BEERSE, Belgium, December 12, 2011  -

﻿Benefit of bortezomib, in combination with melphalan and prednisone (VMP), seen across multiple patient subgroups regardless of subsequent extensive therapy
Janssen-Cilag International NV announced today that treatment with VELCADE(bortezomib), in combination with melphalan and prednisone (VMP), delivered a significant long-term overall survival (OS) benefit of 13.3 months (HR 0.695, p=0.0004), .... Source &nbsp;: <a href="http://pr.gaeatimes.com/landmark-vista-trial-shows-significant-long-term-overall-survival-benefit-of-velcade%c2%ae-bortezomib-in-patients-with-previously-untreated-multiple-myeloma-54712/" title="Landmark VISTA Trial Shows Significant Long-Term Overall Survival Benefit of VELCADE® (Bortezomib) in Patients With Previously Untreated Multiple Myeloma">Gaea News Network</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/landmark-vista-trial-shows-significant-long-term-overall-survival-benefit-of-velcade%c2%ae-bortezomib-in-patients-with-previously-untreated-multiple-myeloma-54712/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Cardiac Rhythm Management Market Worth 27.8 Billion Dollars by 2021, Says visiongain Report</title>
		<link>http://pr.gaeatimes.com/cardiac-rhythm-management-market-worth-278-billion-dollars-by-2021-says-visiongain-report-54628/</link>
		<comments>http://pr.gaeatimes.com/cardiac-rhythm-management-market-worth-278-billion-dollars-by-2021-says-visiongain-report-54628/#comments</comments>
		<pubDate>Sat, 10 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Visiongain</dc:creator>
		
		<category><![CDATA[Banking and Financial Services]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Technology]]></category>

		<category><![CDATA[December 10]]></category>

		<category><![CDATA[London]]></category>

		<category><![CDATA[United Kingdom]]></category>

		<category><![CDATA[Visiongain]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/cardiac-rhythm-management-market-worth-278-billion-dollars-by-2021-says-visiongain-report-54628/</guid>
		<description><![CDATA[LONDON, December 10, 2011  -
﻿

www.visiongain.com/Report/728/Cardiac-Rhythm-Management-Devices-World-Market-Outlook-2011-2021
A new report by visiongain, a London-based business information provider, predicts the global cardiac rhythm management market to be worth $27.8bn by 2021. The market generated $14.6bn in 2010 according to Cardiac Rhythm Management Devices: World Market Outlook, 2011-2021, published in December 2011.
Cardiac rhythm management is a well established segment .... <a href="http://pr.gaeatimes.com/cardiac-rhythm-management-market-worth-278-billion-dollars-by-2021-says-visiongain-report-54628/">Source article on Gaea Times at  &nbsp;: Cardiac Rhythm Management Market Worth 27.8 Billion Dollars by 2021, Says visiongain Report</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/cardiac-rhythm-management-market-worth-278-billion-dollars-by-2021-says-visiongain-report-54628/feed/</wfw:commentRss>
		</item>
		<item>
		<title>NHS National Innovation Centre Estimates Sequana Medical&#8217;s ALFApump® System Could Save the NHS £50 Million in ascites Care Annually</title>
		<link>http://pr.gaeatimes.com/nhs-national-innovation-centre-estimates-sequana-medicals-alfapump%c2%ae-system-could-save-the-nhs-50-million-in-ascites-care-annually-54588/</link>
		<comments>http://pr.gaeatimes.com/nhs-national-innovation-centre-estimates-sequana-medicals-alfapump%c2%ae-system-could-save-the-nhs-50-million-in-ascites-care-annually-54588/#comments</comments>
		<pubDate>Fri, 09 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Sequana Medical Ag</dc:creator>
		
		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[New Products / Services]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Surveys / Polls / Research]]></category>

		<category><![CDATA[December 9]]></category>

		<category><![CDATA[Sequana Medical Ag]]></category>

		<category><![CDATA[Switzerland]]></category>

		<category><![CDATA[United Kingdom]]></category>

		<category><![CDATA[Zurich]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/nhs-national-innovation-centre-estimates-sequana-medicals-alfapump%c2%ae-system-could-save-the-nhs-50-million-in-ascites-care-annually-54588/</guid>
		<description><![CDATA[ZURICH, December 9, 2011  -
NHS National Innovation Centre supports the cost effectiveness of Sequana Medical&#8217;s ALFApump System

Sequana Medical announced today the findings of an independent economic assessment of the ALFApump System commissioned by the National Innovation Centre, the NHS organization which supports innovators, commissioners, and clinicians to speed up the development and use of ... <a href="http://pr.gaeatimes.com/nhs-national-innovation-centre-estimates-sequana-medicals-alfapump%c2%ae-system-could-save-the-nhs-50-million-in-ascites-care-annually-54588/" title="NHS National Innovation Centre Estimates Sequana Medical&#8217;s ALFApump® System Could Save the NHS £50 Million in ascites Care Annually">Read more >></a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/nhs-national-innovation-centre-estimates-sequana-medicals-alfapump%c2%ae-system-could-save-the-nhs-50-million-in-ascites-care-annually-54588/feed/</wfw:commentRss>
		</item>
		<item>
		<title>ConvaTec Awarded MediWales 2011 Innovation Award</title>
		<link>http://pr.gaeatimes.com/convatec-awarded-mediwales-2011-innovation-award-54598/</link>
		<comments>http://pr.gaeatimes.com/convatec-awarded-mediwales-2011-innovation-award-54598/#comments</comments>
		<pubDate>Fri, 09 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Convatec</dc:creator>
		
		<category><![CDATA[Awards]]></category>

		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Cardiff]]></category>

		<category><![CDATA[ConvaTec]]></category>

		<category><![CDATA[December 9]]></category>

		<category><![CDATA[wales]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/convatec-awarded-mediwales-2011-innovation-award-54598/</guid>
		<description><![CDATA[CARDIFF, Wales, December 9, 2011  -


ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced that it received the 2011 Innovation Award from MediWales for AQUACEL® SURGICAL* and AQUACEL® Ag SURGICAL cover dressings. The Innovation Award recognises the development of an innovative technology, design and/or process that ... <a href="http://pr.gaeatimes.com/convatec-awarded-mediwales-2011-innovation-award-54598/">Read : ConvaTec Awarded MediWales 2011 Innovation Award</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/convatec-awarded-mediwales-2011-innovation-award-54598/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Life Technologies Chooses Rhenium to Distribute Products in Israel</title>
		<link>http://pr.gaeatimes.com/life-technologies-chooses-rhenium-to-distribute-products-in-israel-54567/</link>
		<comments>http://pr.gaeatimes.com/life-technologies-chooses-rhenium-to-distribute-products-in-israel-54567/#comments</comments>
		<pubDate>Thu, 08 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Life Technologies Corporation</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Licensing / Marketing Agreements]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[December 8]]></category>

		<category><![CDATA[Facebook]]></category>

		<category><![CDATA[Glasgow]]></category>

		<category><![CDATA[life technologies corporation]]></category>

		<category><![CDATA[scotland]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/life-technologies-chooses-rhenium-to-distribute-products-in-israel-54567/</guid>
		<description><![CDATA[GLASGOW, Scotland, December 8, 2011  -


Life to provide broader product portfolio to Israeli customers through one distributor.
Life Technologies Corporation (Nasdaq: LIFE) today announced that it has chosen Rhenium as the principal distributor of its product portfolio for the Israeli market.  The deal represents Life&#8217;s continued growth in the region.
&#8220;We want our customers to be ... <a href="http://pr.gaeatimes.com/life-technologies-chooses-rhenium-to-distribute-products-in-israel-54567/">Original source on Gaea Times at  : Life Technologies Chooses Rhenium to Distribute Products in Israel</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/life-technologies-chooses-rhenium-to-distribute-products-in-israel-54567/feed/</wfw:commentRss>
		</item>
		<item>
		<title>InGen BioSciences Group Acquires Tetanos Quick Stick® (TQS)</title>
		<link>http://pr.gaeatimes.com/ingen-biosciences-group-acquires-tetanos-quick-stick%c2%ae-tqs-54427/</link>
		<comments>http://pr.gaeatimes.com/ingen-biosciences-group-acquires-tetanos-quick-stick%c2%ae-tqs-54427/#comments</comments>
		<pubDate>Wed, 07 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Ingen Biosciences</dc:creator>
		
		<category><![CDATA[Acquisitions / Mergers / Takeovers]]></category>

		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Investors]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Chilly-mazarin]]></category>

		<category><![CDATA[December 7]]></category>

		<category><![CDATA[France]]></category>

		<category><![CDATA[Ingen Biosciences]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/ingen-biosciences-group-acquires-tetanos-quick-stick%c2%ae-tqs-54427/</guid>
		<description><![CDATA[CHILLY-MAZARIN, France, December 7, 2011  -

InGen BioSciences today announced that it has acquired the leading European In Vitro Diagnostic Tetanos Quick Stick®test which ensures optimal management of at risk patients in case of wound in Emergency Departments.
Founded in 2001, InGen BioSciences is specialized in the development of mono and multiparametric in vitro diagnostic tests. .... <a href="http://pr.gaeatimes.com/ingen-biosciences-group-acquires-tetanos-quick-stick%c2%ae-tqs-54427/">Source &nbsp;: InGen BioSciences Group Acquires Tetanos Quick Stick® (TQS)</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/ingen-biosciences-group-acquires-tetanos-quick-stick%c2%ae-tqs-54427/feed/</wfw:commentRss>
		</item>
		<item>
		<title>NHS Contractor Outsources IT to Focus on Delivering Patient Care</title>
		<link>http://pr.gaeatimes.com/nhs-contractor-outsources-it-to-focus-on-delivering-patient-care-54462/</link>
		<comments>http://pr.gaeatimes.com/nhs-contractor-outsources-it-to-focus-on-delivering-patient-care-54462/#comments</comments>
		<pubDate>Wed, 07 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Intechnology</dc:creator>
		
		<category><![CDATA[Business]]></category>

		<category><![CDATA[Contracts]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Investors]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[New Products / Services]]></category>

		<category><![CDATA[Outsourcing Businesses]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Technology]]></category>

		<category><![CDATA[Telecommunications]]></category>

		<category><![CDATA[Telecommunications Carriers and Services]]></category>

		<category><![CDATA[December 7]]></category>

		<category><![CDATA[England]]></category>

		<category><![CDATA[Harrogate]]></category>

		<category><![CDATA[Intechnology]]></category>

		<category><![CDATA[United Kingdom]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/nhs-contractor-outsources-it-to-focus-on-delivering-patient-care-54462/</guid>
		<description><![CDATA[HARROGATE, England, December 7, 2011  -

Hosted IT Environment Allows Growth of The Practice to Operate 60 Surgeries, Specialist Clinics and Walk-in Centres Across the UK
A community-based healthcare service provider with 60 surgeries and walk-in centres across the UK, has outsourced its IT infrastructure to Cloud services specialist InTechnology so it can concentrate on improving ... <a href="http://pr.gaeatimes.com/nhs-contractor-outsources-it-to-focus-on-delivering-patient-care-54462/">Original source on Gaea Times at  : NHS Contractor Outsources IT to Focus on Delivering Patient Care</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/nhs-contractor-outsources-it-to-focus-on-delivering-patient-care-54462/feed/</wfw:commentRss>
		</item>
		<item>
		<title>HealthpointCapital Acquires Blue Belt Technologies, Inc. and Appoints Eric B. Timko as President and CEO</title>
		<link>http://pr.gaeatimes.com/healthpointcapital-acquires-blue-belt-technologies-inc-and-appoints-eric-b-timko-as-president-and-ceo-54480/</link>
		<comments>http://pr.gaeatimes.com/healthpointcapital-acquires-blue-belt-technologies-inc-and-appoints-eric-b-timko-as-president-and-ceo-54480/#comments</comments>
		<pubDate>Wed, 07 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Healthpointcapital Llc</dc:creator>
		
		<category><![CDATA[Acquisitions / Mergers / Takeovers]]></category>

		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Investors]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Personnel Announcements]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[December 7]]></category>

		<category><![CDATA[Healthpointcapital Llc]]></category>

		<category><![CDATA[New York]]></category>

		<category><![CDATA[New York And Pittsburgh]]></category>

		<category><![CDATA[Pennsylvania]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/healthpointcapital-acquires-blue-belt-technologies-inc-and-appoints-eric-b-timko-as-president-and-ceo-54480/</guid>
		<description><![CDATA[NEW YORK and PITTSBURGH, December 7, 2011  -

HealthpointCapital, LLC (&#8221;HealthpointCapital&#8221;) announced today the purchase of Blue Belt Technologies, Inc. (&#8221;Blue Belt&#8221; or &#8220;Company&#8221;). Blue Belt is developing the next generation of &#8220;smart&#8221; surgical instruments for use initially in orthopedic procedures and then for other surgical specialties including neurosurgery and otolaryngology (&#8221;ENT&#8221;). Terms of the .... Original source &nbsp;: <a href="http://pr.gaeatimes.com/healthpointcapital-acquires-blue-belt-technologies-inc-and-appoints-eric-b-timko-as-president-and-ceo-54480/">HealthpointCapital Acquires Blue Belt Technologies, Inc. and Appoints Eric B. Timko as President and CEO</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/healthpointcapital-acquires-blue-belt-technologies-inc-and-appoints-eric-b-timko-as-president-and-ceo-54480/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Steamed-up Specs Wiped-Out for Good</title>
		<link>http://pr.gaeatimes.com/steamed-up-specs-wiped-out-for-good-54326/</link>
		<comments>http://pr.gaeatimes.com/steamed-up-specs-wiped-out-for-good-54326/#comments</comments>
		<pubDate>Tue, 06 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Essilor</dc:creator>
		
		<category><![CDATA[Business]]></category>

		<category><![CDATA[Consumer Products]]></category>

		<category><![CDATA[Fashion]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Household / Consumer / Cosmetics]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[New Products / Services]]></category>

		<category><![CDATA[Peripherals]]></category>

		<category><![CDATA[Technology]]></category>

		<category><![CDATA[Bristol]]></category>

		<category><![CDATA[December 6]]></category>

		<category><![CDATA[England]]></category>

		<category><![CDATA[Essilor]]></category>

		<category><![CDATA[United Kingdom]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/steamed-up-specs-wiped-out-for-good-54326/</guid>
		<description><![CDATA[BRISTOL, England, December 6, 2011  -

Glasses-wearers&#8217; pet hate banished with new lens
An affliction which plagues spectacle-wearers - the steamed-up lens - could soon be a thing of the past thanks to a new scientific development.
Fogged lenses are a problem shared by glasses-wearers from all walks of life. Celebrities with specs - from Cheryl Cole .... Read the original article &nbsp;: <a href="http://pr.gaeatimes.com/steamed-up-specs-wiped-out-for-good-54326/">here</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/steamed-up-specs-wiped-out-for-good-54326/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Biospace Lab Collaborates With ImaBio Group to Develop a Unique X-Ray Tomographic Module for its Preclinical Imaging System</title>
		<link>http://pr.gaeatimes.com/biospace-lab-collaborates-with-imabio-group-to-develop-a-unique-x-ray-tomographic-module-for-its-preclinical-imaging-system-54331/</link>
		<comments>http://pr.gaeatimes.com/biospace-lab-collaborates-with-imabio-group-to-develop-a-unique-x-ray-tomographic-module-for-its-preclinical-imaging-system-54331/#comments</comments>
		<pubDate>Tue, 06 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Biospace Lab</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Business]]></category>

		<category><![CDATA[Clinical Trials / Medical Discoveries]]></category>

		<category><![CDATA[Contracts]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Investors]]></category>

		<category><![CDATA[Joint Ventures]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[New Products / Services]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Biospace Lab]]></category>

		<category><![CDATA[December 6]]></category>

		<category><![CDATA[France]]></category>

		<category><![CDATA[Paris]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/biospace-lab-collaborates-with-imabio-group-to-develop-a-unique-x-ray-tomographic-module-for-its-preclinical-imaging-system-54331/</guid>
		<description><![CDATA[PARIS, December 6, 2011  -
Biospace Lab and the ImaBio Group (IPHC, Strasbourg) are pleased to announce they are collaborating on the development of a new X-ray tomographic imaging module for use with the Biospace Lab PhotonIMAGER&#8482; OPTIMA system, a fully modular and versatile preclinical optical imager developed for real-time in vivo luminescence or fluorescence .... <a href="http://pr.gaeatimes.com/biospace-lab-collaborates-with-imabio-group-to-develop-a-unique-x-ray-tomographic-module-for-its-preclinical-imaging-system-54331/">Source article on Gaea Times at  &nbsp;: Biospace Lab Collaborates With ImaBio Group to Develop a Unique X-Ray Tomographic Module for its Preclinical Imaging System</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/biospace-lab-collaborates-with-imabio-group-to-develop-a-unique-x-ray-tomographic-module-for-its-preclinical-imaging-system-54331/feed/</wfw:commentRss>
		</item>
		<item>
		<title>MarketsandMarkets: API Market is Expected to Reach $159.08 Billion by 2016</title>
		<link>http://pr.gaeatimes.com/marketsandmarkets-api-market-is-expected-to-reach-15908-billion-by-2016-54349/</link>
		<comments>http://pr.gaeatimes.com/marketsandmarkets-api-market-is-expected-to-reach-15908-billion-by-2016-54349/#comments</comments>
		<pubDate>Tue, 06 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Marketsandmarkets</dc:creator>
		
		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Surveys / Polls / Research]]></category>

		<category><![CDATA[Dallas]]></category>

		<category><![CDATA[December 6]]></category>

		<category><![CDATA[MarketsandMarkets]]></category>

		<category><![CDATA[texas]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/marketsandmarkets-api-market-is-expected-to-reach-15908-billion-by-2016-54349/</guid>
		<description><![CDATA[DALLAS, December 6, 2011  -
The report &#8220;Active Pharmaceutical Ingredient (API) Market Trends, Competitive Landscape and Global Forecasts (2011-2016)&#8220; analyzes and studies the major market drivers, restraints, and opportunities in regions such as North America, Europe, Asia, Japan and Rest of the world.

Browse market data tables and in-depth TOC on Active Pharmaceutical Ingredient (API) Market Trends, .... <a href="http://pr.gaeatimes.com/marketsandmarkets-api-market-is-expected-to-reach-15908-billion-by-2016-54349/">Original article on Gaea Times at  &nbsp;: MarketsandMarkets: API Market is Expected to Reach $159.08 Billion by 2016</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/marketsandmarkets-api-market-is-expected-to-reach-15908-billion-by-2016-54349/feed/</wfw:commentRss>
		</item>
	</channel>
</rss>

